Show simple item record

dc.contributor.authorFlaten, Gøril Eide
dc.contributor.authorChang, Ting-Tung
dc.contributor.authorPhillips, William T.
dc.contributor.authorBrandl, Martin
dc.contributor.authorBao, Ande
dc.contributor.authorGoins, Beth
dc.date.accessioned2016-03-16T14:01:28Z
dc.date.available2016-03-16T14:01:28Z
dc.date.issued2012-12-05
dc.description.abstractContext: Camptothecin (CPT) represents a potent anticancer drug. Its therapeutic use however is impaired by both drug solubility, hydrolysis and protein interactions in vivo. Use of liposomes as drug formulation approach could overcome some of these challenges. <p>Objective: The objective of this study was to perform a mechanistic study of the incorporation and retention of the lipophilic parent CPT-compound in different liposome formulations using radiolabeled CPT and thus be able to identify promising CPT delivery systems. In this context we also wanted to establish an appropriate mouse tumor model, in vivo scintigraphic imaging and biodistribution methodology for testing the most promising formulation. <p>Materials and methods: CPT retention in various liposome formulations following incubation in buffer and serum was determined. The HT-29 mouse tumor model, 111In-labeled liposomes as well as 3H-labeled CPT were used to investigate the biodistribution of liposomes and drug. <p>Results and discussion: The ability of different liposome formulations to retain CPT in buffer was influenced by the lipid concentration and the drug:lipid ratio rather than lipid composition. The tested formulations were cleared from the blood in the following order:CPT-solutionCPTliposomes 111In-labeled liposomes, and liposomes mainly accumulated in liver. <p>Conclusion: Lipid composition did not influence CPT retention to the same extent as earlier observed in incorporation studies. The set up for the biodistribution study works well and is suited for future in vivo studies on CPT liposomes. The biodistribution study showed that liposomes circulated longer than free drug, but premature release of drug from liposomes occurred. Further studies to develop formulations with higher retention potential and prolonged circulation are desired.en_US
dc.descriptionAccepted manuscript version. Published version available at <a href=http://dx.doi.org/10.3109/08982104.2012.742537>http://dx.doi.org/10.3109/08982104.2012.742537</a>en_US
dc.identifier.citationJournal of liposome research 2013, 23(1):70-81en_US
dc.identifier.cristinIDFRIDAID 1033180
dc.identifier.doi10.3109/08982104.2012.742537
dc.identifier.issn0898-2104
dc.identifier.urihttps://hdl.handle.net/10037/8984
dc.identifier.urnURN:NBN:no-uit_munin_8539
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medisinske Fag: 700en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.titleLiposomal formulations of poorly soluble camptothecin: drug retention and biodistributionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record